Table 1 Study cohort characteristics
Insulin Group (n = 222) | Switching Group (n = 318) | Metformin Group (n = 626) | |
|---|---|---|---|
Age at pregnancy, y, mean (SD) | 34.48 (4.02) | 34.05 (4.23) | 33.51 (4.31) |
Age at pregnancy, y, No. (%) | |||
20–29 | 29 (13.06) | 48 (15.09) | 129 (20.61) |
30–34 | 86 (38.74) | 124 (38.99) | 258 (41.21) |
35–39 | 90 (40.54) | 123 (38.68) | 189 (30.19) |
40–44 | 17 (7.66) | 23 (7.23) | 50 (7.99) |
Duration of diabetes, y, median (IQR) | 3.65 (4.58) | 3.10 (3.84) | 1.49 (3.34) |
Baseline comorbidities, No. (%) | |||
Hypertension | 46 (20.72) | 84 (26.42) | 114 (18.21) |
Hyperlipidemia | 110 (49.55) | 157 (49.37) | 145 (23.16) |
Retinopathy | 24 (10.81) | 21 (6.60) | 26 (4.15) |
Nephropathy | < 5 (< 2.25)a | < 5 (< 1.57)a | 8 (1.28) |
Neuropathy | 5 (2.25) | < 5 (< 2.25)a | 0 (0) |
Baseline medications, No. (%) | |||
Aspirin | 5 (2.25) | 9 (2.83) | 48 (7.67) |
Statin | 17 (7.66) | 50 (15.72) | 38 (6.07) |
Ezetimibe | < 5 (< 2.25)a | < 5 (< 1.57)a | 0 (0) |
Fibrate | 0 (0) | 0 (0) | 0 (0) |
ACEI/ARB | 7 (3.15) | 18 (5.66) | 26 (4.15) |
Beta-blockers | < 5 (< 2.25)a | 10 (3.14) | 19 (3.04) |
Calcium channel blockers | 9 (4.05) | 27 (8.49) | 24 (3.83) |
Diureticsb | < 5 (< 2.25)a | < 5 (< 1.57)a | 12 (1.92) |